New horizons for old drugs and drug leads.
暂无分享,去创建一个
[1] J. Rhim,et al. HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects. , 2013, Journal of Controlled Release.
[2] Sahdeo Prasad,et al. Cancer drug discovery by repurposing: teaching new tricks to old dogs. , 2013, Trends in pharmacological sciences.
[3] Xiaohu Zhang,et al. Cyclopamine, a naturally occurring alkaloid, and its analogues may find wide applications in cancer therapy. , 2013, Current topics in medicinal chemistry.
[4] Noel Southall,et al. Rapid Identification of Antifungal Compounds against Exserohilum rostratum Using High Throughput Drug Repurposing Screens , 2013, PloS one.
[5] Melvin J. Yu,et al. From micrograms to grams: scale-up synthesis of eribulin mesylate. , 2013, Natural product reports.
[6] J. Lambert. Drug‐conjugated antibodies for the treatment of cancer , 2013, British journal of clinical pharmacology.
[7] G. Berg,et al. A study of the bacterial community in the root system of the maytansine containing plant Putterlickia verrucosa. , 2013, Phytochemistry.
[8] F. Reyes,et al. Isolation and first total synthesis of PM050489 and PM060184, two new marine anticancer compounds. , 2013, Journal of the American Chemical Society.
[9] David Cavalla,et al. Predictive methods in drug repurposing: gold mine or just a bigger haystack? , 2013, Drug discovery today.
[10] David J Newman,et al. Natural products: a continuing source of novel drug leads. , 2013, Biochimica et biophysica acta.
[11] H. Abboud. Synthetic oleanane triterpenoids: magic bullets or not? , 2013, Kidney international.
[12] C. Rudin,et al. Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors , 2013, Clinical Cancer Research.
[13] J. McMurray,et al. Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) , 2013, American Journal of Nephrology.
[14] Li Huang,et al. New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1. , 2013, Journal of medicinal chemistry.
[15] L. Costa-Lotufo,et al. Overview of the therapeutic potential of piplartine (piperlongumine). , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[16] Herbert Waldmann,et al. Biology‐Oriented Synthesis of a Tetrahydroisoquinoline‐Based Compound Collection Targeting Microtubule Polymerization , 2013, Chembiochem : a European journal of chemical biology.
[17] S. Linder,et al. Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells. , 2013, Biochemical and biophysical research communications.
[18] Christine J. Martin,et al. Structure guided design of improved anti-proliferative rapalogs through biosynthetic medicinal chemistry , 2013 .
[19] J. Cummings,et al. A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents , 2013, Dementia and Geriatric Cognitive Disorders.
[20] R. Uzzo,et al. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells , 2013, The Prostate.
[21] U. Tatu,et al. Heat shock protein 90 inhibitors as broad spectrum anti-infectives. , 2012, Current pharmaceutical design.
[22] D. Budman,et al. Trastuzumab-DM1: A Clinical Update of the Novel Antibody-Drug Conjugate for HER2-Overexpressing Breast Cancer , 2012, Molecular medicine.
[23] F. Koehn. Natural Products and Cancer Drug Discovery , 2013 .
[24] Christine J. Martin,et al. Recombinant strains for the enhanced production of bioengineered rapalogs. , 2013, Metabolic engineering.
[25] S. Corey,et al. Drug repurposing in pediatrics and pediatric hematology oncology. , 2013, Drug discovery today.
[26] R. Biggar,et al. Breast cancer in women using digoxin: tumor characteristics and relapse risk , 2013, Breast Cancer Research.
[27] L. Didone,et al. A Repurposing Approach Identifies Off-Patent Drugs with Fungicidal Cryptococcal Activity, a Common Structural Chemotype, and Pharmacological Properties Relevant to the Treatment of Cryptococcosis , 2012, Eukaryotic Cell.
[28] Leonard Katz,et al. Genome-based bioprospecting of microbes for new therapeutics. , 2012, Current opinion in biotechnology.
[29] B. Wilkinson,et al. Bioengineering natural product biosynthetic pathways for therapeutic applications. , 2012, Current opinion in biotechnology.
[30] Young-Soo Hong,et al. New geldanamycin analogs from Streptomyces hygroscopicus. , 2012, Journal of microbiology and biotechnology.
[31] S. Cole,et al. Towards a new tuberculosis drug: pyridomycin – nature's isoniazid , 2012, EMBO molecular medicine.
[32] Gerard D. Wright. Back to the future: a new ‘old’ lead for tuberculosis , 2012, EMBO molecular medicine.
[33] S. Schreiber,et al. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs , 2012, Proceedings of the National Academy of Sciences.
[34] Xi-shi Liu,et al. Histone deacetylase inhibitors as therapeutics for endometriosis , 2012 .
[35] D. Krysan,et al. Antifungal Drug Discovery: Something Old and Something New , 2012, PLoS pathogens.
[36] Kyle Petersen,et al. Repurposing screens identify rifamycins as potential broad-spectrum therapy for multidrug-resistant Acinetobacter baumannii and select agent microorganisms. , 2012, Future microbiology.
[37] R. Biggar,et al. Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix , 2012, International journal of cancer.
[38] Tudor I. Oprea,et al. Drug Repurposing: Far Beyond New Targets for Old Drugs , 2012, The AAPS Journal.
[39] R. Capon. Microbial biodiscovery: back to the future. , 2012, Current topics in medicinal chemistry.
[40] W. Childers,et al. Targeting neurodegenerative diseases: Drug discovery in a challenging arena , 2012 .
[41] D. Mitchison,et al. The chemotherapy of tuberculosis: past, present and future [State of the art]. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[42] M. Marsden,et al. Designed, Synthetically Accessible Bryostatin Analogues Potently Induce Activation of Latent HIV Reservoirs in vitro , 2012, Nature chemistry.
[43] Jeffrey Aubé,et al. Drug repurposing and the medicinal chemist. , 2012, ACS medicinal chemistry letters.
[44] J. O’Grady,et al. Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. , 2012, The Journal of infectious diseases.
[45] Cerasela Zoica Dinu,et al. Digitoxin and its analogs as novel cancer therapeutics , 2012, Experimental Hematology & Oncology.
[46] C. Khosla,et al. Combinatorial biosynthesis of polyketides--a perspective. , 2012, Current opinion in chemical biology.
[47] B. Gicquel,et al. Mycobacterium abscessus: a new antibiotic nightmare. , 2012, The Journal of antimicrobial chemotherapy.
[48] Neil Swanson,et al. Ingenol mebutate gel for actinic keratosis. , 2012, The New England journal of medicine.
[49] David J Newman,et al. Natural products as sources of new drugs over the 30 years from 1981 to 2010. , 2012, Journal of natural products.
[50] J. Kopeček,et al. Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells. , 2012, Biomaterials.
[51] J. Scheuermann,et al. A traceless vascular-targeting antibody-drug conjugate for cancer therapy. , 2012, Angewandte Chemie.
[52] D. Felsher,et al. “Picolog,” a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo , 2012, Oncotarget.
[53] P. Wender,et al. Function Oriented Synthesis: Preparation and Initial Biological Evaluation of New A-Ring-Modified Bryologs. , 2011, Tetrahedron.
[54] R. Santaolalla,et al. TLR signaling: a link between gut microflora, colorectal inflammation and tumorigenesis , 2011 .
[55] Elizabeth I. Parkinson,et al. Runaway ROS as a Selective Anticancer Strategy , 2011, ChemMedChem.
[56] A. Ricart. Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin , 2011, Clinical Cancer Research.
[57] B. Teicher,et al. Antibody Conjugate Therapeutics: Challenges and Potential , 2011, Clinical Cancer Research.
[58] A. Younes,et al. Brentuximab Vedotin (SGN-35) , 2011, Clinical Cancer Research.
[59] R. Lutz,et al. SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies , 2011, Clinical Cancer Research.
[60] M. Sliwkowski,et al. Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer , 2011, Clinical Cancer Research.
[61] K. Hale,et al. Total synthesis of bryostatin 1: a short route. , 2011, Angewandte Chemie.
[62] D. Livermore. Discovery research: the scientific challenge of finding new antibiotics. , 2011, The Journal of antimicrobial chemotherapy.
[63] Philip Raskin,et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. , 2011, The New England journal of medicine.
[64] T. Golub,et al. Selective killing of cancer cells with a small molecule targeting stress response to ROS , 2011, Nature.
[65] S. Chopra,et al. Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. , 2011, The Journal of antimicrobial chemotherapy.
[66] Lavonne Patton,et al. New sources of drugs for hematologic malignancies. , 2011, Blood.
[67] Z. Deng,et al. Identification and characterization of the pyridomycin biosynthetic gene cluster of Streptomyces pyridomyceticus NRRL B-2517. , 2011, The Journal of biological chemistry.
[68] Young-Soo Hong,et al. New non-quinone geldanamycin analogs from genetically engineered Streptomyces hygroscopicus , 2011, The Journal of Antibiotics.
[69] Edward Giovannucci,et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. , 2011, Cancer discovery.
[70] Francis S. Collins,et al. Mining for therapeutic gold , 2011, Nature Reviews Drug Discovery.
[71] Sean Ekins,et al. Finding Promiscuous Old Drugs for New Uses , 2011, Pharmaceutical Research.
[72] B. Grimberg,et al. Expanding the Antimalarial Drug Arsenal—Now, But How? , 2011, Pharmaceuticals.
[73] D. Warnock,et al. Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD , 2011, American Journal of Nephrology.
[74] P. Wender,et al. Translating Nature's Library: The Bryostatins and Function-Oriented Synthesis. , 2011, Israel journal of chemistry.
[75] F. Kelleher. Hedgehog signaling and therapeutics in pancreatic cancer. , 2011, Carcinogenesis.
[76] Vishal A. Verma,et al. Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity , 2011, Proceedings of the National Academy of Sciences.
[77] Melvin J. Yu,et al. Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor model. , 2011, Bioorganic & medicinal chemistry letters.
[78] Melvin J. Yu,et al. Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility. , 2011, Bioorganic & medicinal chemistry letters.
[79] Melvin J. Yu,et al. Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo. , 2011, Bioorganic & medicinal chemistry letters.
[80] A. Gould,et al. Targeting the hedgehog pathway: the development of cyclopamine and the development of anti-cancer drugs targeting the hedgehog pathway. , 2011, Mini reviews in medicinal chemistry.
[81] D. Nielsen,et al. Trastuzumab emtansine, tumor-activated prodrug (TAP) immunoconjungate, oncolytic , 2011 .
[82] G. Feldmann,et al. Agents targeting the Hedgehog pathway for pancreatic cancer treatment. , 2010, Current opinion in investigational drugs.
[83] J. Switzer,et al. Minocycline to Improve Neurologic Outcome in Stroke (MINOS): A Dose-Finding Study , 2010, Stroke.
[84] D. Newman,et al. Plant Natural Products in Anticancer Drug Discovery , 2010 .
[85] Bethan Hughes. Antibody–drug conjugates for cancer: poised to deliver? , 2010, Nature Reviews Drug Discovery.
[86] Gert Storm,et al. Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release , 2010, Pharmaceutical Research.
[87] Alexey Lugovskoy,et al. Design of next-generation protein therapeutics. , 2010, Current opinion in chemical biology.
[88] Stephen C Alley,et al. Antibody-drug conjugates: targeted drug delivery for cancer. , 2010, Current opinion in chemical biology.
[89] Yeo Joon Yoon,et al. Biosynthesis of rapamycin and its regulation: past achievements and recent progress , 2010, The Journal of Antibiotics.
[90] M. Nagarkatti,et al. Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner , 2010, PloS one.
[91] A. Giannis,et al. Cyclopamine and hedgehog signaling: chemistry, biology, medical perspectives. , 2010, Angewandte Chemie.
[92] Clay S. Bennett,et al. Design, synthesis, and biological evaluation of EF- and ABEF- analogues of (+)-spongistatin 1. , 2010, Organic letters.
[93] K. Hale,et al. New approaches to the total synthesis of the bryostatin antitumor macrolides. , 2010, Chemistry, an Asian journal.
[94] Jan Albert,et al. Can the further clinical development of bevirimat be justified? , 2010, AIDS.
[95] Michael A Fischbach,et al. Natural products version 2.0: connecting genes to molecules. , 2010, Journal of the American Chemical Society.
[96] J. Lambert. Antibody-maytansinoid conjugates: A new strategy for the treatment of cancer , 2010, Drugs of the Future.
[97] Teicher Ba. Antibody-drug conjugate targets. , 2009 .
[98] David J Newman,et al. Natural product scaffolds as leads to drugs. , 2009, Future medicinal chemistry.
[99] Keduo Qian,et al. Plant-derived triterpenoids and analogues as antitumor and anti-HIV agents. , 2009, Natural product reports.
[100] R. Gebhardt,et al. From teratogens to potential therapeutics: natural inhibitors of the Hedgehog signaling network come of age. , 2009, Planta medica.
[101] Arsène Burny,et al. Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection , 2009, PloS one.
[102] Jeanne A. Ferguson,et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). , 2009, Journal of medicinal chemistry.
[103] P. Senter. Potent antibody drug conjugates for cancer therapy. , 2009, Current opinion in chemical biology.
[104] Li Huang,et al. Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents. , 2009, Journal of medicinal chemistry.
[105] D. Newman,et al. Impact of natural products on developing new anti-cancer agents. , 2009, Chemical reviews.
[106] T. Triche,et al. Characterization of NVX‐207, a novel betulinic acid‐derived anti‐cancer compound , 2009, European journal of clinical investigation.
[107] E. Graziani,et al. Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs. , 2009, Natural product reports.
[108] James T. Elder,et al. Lack of evidence for activation of the hedgehog pathway in psoriasis. , 2009, The Journal of investigative dermatology.
[109] J. McAlpine. Advances in the understanding and use of the genomic base of microbial secondary metabolite biosynthesis for the discovery of new natural products. , 2009, Journal of natural products.
[110] S. Maffioli,et al. Bacterial RNA polymerase inhibitors: an organized overview of their structure, derivatives, biological activity and current clinical development status. , 2009, Current medicinal chemistry.
[111] Hugh S. Taylor,et al. Experimental Murine Endometriosis Induces DNA Methylation and Altered Gene Expression in Eutopic Endometrium1 , 2009, Biology of reproduction.
[112] T. Molinski,et al. Drug development from marine natural products , 2009, Nature Reviews Drug Discovery.
[113] Guangbin Dong,et al. Total synthesis of bryostatin 16 using atom-economical and chemoselective approaches , 2008, Nature.
[114] T. Knobloch,et al. Iconography : The chemistry and biology of the maytansinoid antitumor agents , 2008 .
[115] Mohammad Nur-E-Alam,et al. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors. , 2008, Journal of medicinal chemistry.
[116] P. Wender,et al. Practical Synthesis of Prostratin, DPP, and Their Analogs, Adjuvant Leads Against Latent HIV , 2008, Science.
[117] D. Alkon,et al. Analysis of long-term cognitive-enhancing effects of bryostatin-1 on the rabbit (Oryctolagus cuniculus) nictitating membrane response , 2008, Behavioural pharmacology.
[118] J. Lord,et al. Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells , 2008, Molecular Cancer Therapeutics.
[119] Christine J. Martin,et al. Molecular characterization of macbecin as an Hsp90 inhibitor. , 2008, Journal of medicinal chemistry.
[120] A. Maitra,et al. Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer. , 2008, Bioorganic & medicinal chemistry.
[121] Young‐Tae Chang,et al. Synthesis and anticancer activity studies of cyclopamine derivatives. , 2008, Bioorganic & medicinal chemistry letters.
[122] A. Awada,et al. Novel cytotoxic drugs: old challenges, new solutions. , 2008, Cancer treatment reviews.
[123] D. Rubinsztein,et al. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. , 2008, Human molecular genetics.
[124] M. Butler. Natural products to drugs: natural product-derived compounds in clinical trials. , 2005, Natural product reports.
[125] S. Wetzel,et al. Biology-inspired synthesis of compound libraries , 2008, Cellular and Molecular Life Sciences.
[126] Keduo Qian,et al. Anti-AIDS agents 73: structure-activity relationship study and asymmetric synthesis of 3-O-monomethylsuccinyl-betulinic acid derivatives. , 2007, Bioorganic & medicinal chemistry letters.
[127] M. Sporn,et al. The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent , 2007, Molecular Cancer Therapeutics.
[128] D. Baker,et al. The value of natural products to future pharmaceutical discovery. , 2007, Natural product reports.
[129] M. Boaz,et al. MINOCYCLINE TREATMENT IN ACUTE STROKE : AN OPEN-LABEL, EVALUATOR-BLINDED STUDY. Authors' reply , 2008 .
[130] M. Ratain,et al. Rapamycin: Something Old, Something New, Sometimes Borrowed and Now Renewed , 2007, Clinical pharmacology and therapeutics.
[131] Z. Lu,et al. Altered expression of HOXA10 in endometriosis: potential role in decidualization. , 2007, Molecular human reproduction.
[132] C. Iacobuzio-Donahue,et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. , 2007, Cancer research.
[133] D. Alkon,et al. PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. , 2007, Trends in pharmacological sciences.
[134] J. Montaner. Stroke biomarkers: can they help us to guide stroke thrombolysis? , 2006, Timely topics in medicine. Cardiovascular diseases.
[135] D. Pompliano,et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.
[136] Lee L. Rubin,et al. Targeting the Hedgehog pathway in cancer , 2006, Nature Reviews Drug Discovery.
[137] J. Weinberg,et al. Cyclopamine: inhibiting hedgehog in the treatment of psoriasis. , 2006, Cutis.
[138] Ruth Duncan,et al. Polymer conjugates as anticancer nanomedicines , 2006, Nature Reviews Cancer.
[139] I. Rayment,et al. Actin-targeting natural products: structures, properties and mechanisms of action , 2006, Cellular and Molecular Life Sciences CMLS.
[140] S. Danishefsky,et al. Small molecule natural products in the discovery of therapeutic agents: the synthesis connection. , 2006, The Journal of organic chemistry.
[141] James R. Porter,et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. , 2006, Journal of medicinal chemistry.
[142] M. Gheorghiade,et al. Contemporary Use of Digoxin in the Management of Cardiovascular Disorders , 2006, Circulation.
[143] Herbert Waldmann,et al. Charting Biological and Chemical Space: PSSC and SCONP as Guiding Principles for the Development of Compound Collections Based on Natural Product Scaffolds , 2006 .
[144] Li Huang,et al. Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives. , 2006, Bioorganic & medicinal chemistry.
[145] J. Montaner. Latest advances and research in stroke: Focus on diagnostic and therapeutic targets. , 2006, Drug news & perspectives.
[146] D. Alkon,et al. Bryostatin-1: pharmacology and therapeutic potential as a CNS drug. , 2006, CNS drug reviews.
[147] Cragg Gm,et al. Natural products from marine invertebrates and microbes as modulators of antitumor targets. , 2006 .
[148] F. Khanim,et al. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. , 2005, Blood.
[149] David E. Martin,et al. The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV , 2005, Expert opinion on investigational drugs.
[150] M. Sporn,et al. Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. , 2005, Bioorganic & medicinal chemistry letters.
[151] Perumal Yogeeswari,et al. Betulinic acid and its derivatives: a review on their biological properties. , 2005, Current medicinal chemistry.
[152] Herbert Waldmann,et al. Compound library development guided by protein structure similarity clustering and natural product structure. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[153] A. Demain. Pickles, pectin, and penicillin. , 2004, Annual review of microbiology.
[154] D. Alkon,et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[155] David J Newman,et al. Marine natural products and related compounds in clinical and advanced preclinical trials. , 2004, Journal of natural products.
[156] P. Parsons,et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. , 2004, Cancer research.
[157] M. Konopleva,et al. Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-γ expression , 2004 .
[158] David J Newman,et al. A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. , 2004, Journal of natural products.
[159] Xin-Yun Huang,et al. Discovery of potent cell migration inhibitors through total synthesis: lessons from structure-activity studies of (+)-migrastatin. , 2004, Journal of the American Chemical Society.
[160] R. Cichewicz,et al. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection , 2004, Medicinal research reviews.
[161] Á. Ravelo,et al. Recent studies on natural products as anticancer agents. , 2004, Current topics in medicinal chemistry.
[162] L. Meijer. Le cycle de division cellulaire et sa régulation , 2006 .
[163] P. Wender,et al. A new synthetic approach to the C ring of known as well as novel bryostatin analogues. , 2003, Organic letters.
[164] Stuart L Schreiber,et al. Discovery of an inhibitor of a transcription factor using small molecule microarrays and diversity-oriented synthesis. , 2003, Journal of the American Chemical Society.
[165] A. Färnert,et al. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports , 2003, BMJ : British Medical Journal.
[166] Gabriel Fenteany,et al. Small-molecule inhibitors of actin dynamics and cell motility. , 2003, Current topics in medicinal chemistry.
[167] A. Mayweg,et al. A concise, selective synthesis of the polyketide spacer domain of a potent bryostatin analogue. , 2003, Organic letters.
[168] K. Yeung,et al. Actin-binding marine macrolides: total synthesis and biological importance. , 2002, Angewandte Chemie.
[169] Herbert Waldmann,et al. Natural product guided compound library development. , 2002, Current medicinal chemistry.
[170] David J Newman,et al. Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy. , 2002, Current cancer drug targets.
[171] Jussi Taipale,et al. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. , 2002, Genes & development.
[172] P. Wender,et al. The practical synthesis of a novel and highly potent analogue of bryostatin. , 2002, Journal of the American Chemical Society.
[173] Herbert Waldmann,et al. From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. , 2002, Angewandte Chemie.
[174] Y. Korin,et al. Effects of Prostratin on T-Cell Activation and Human Immunodeficiency Virus Latency , 2002, Journal of Virology.
[175] Mark Frigerio,et al. The chemistry and biology of the bryostatin antitumour macrolides. , 2002, Natural product reports.
[176] H. Waldmann,et al. Natural products are biologically validated starting points in structural space for compound library development: solid-phase synthesis of dysidiolide-derived phosphatase inhibitors. , 2002, Angewandte Chemie.
[177] P. Clemons,et al. A one-bead, one-stock solution approach to chemical genetics: part 2. , 2001, Chemistry & biology.
[178] John A. Tallarico,et al. A one-bead, one-stock solution approach to chemical genetics: part 1. , 2001, Chemistry & biology.
[179] M. Boyd,et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. , 2001, Blood.
[180] F. Uckun,et al. Spongistatins as tubulin targeting agents. , 2001, Current pharmaceutical design.
[181] Y. Feng,et al. Use of biomimetic diversity-oriented synthesis to discover galanthamine-like molecules with biological properties beyond those of the natural product. , 2001, Journal of the American Chemical Society.
[182] J. Pezzuto,et al. Betulinic acid reduces ultraviolet-C-induced DNA breakage in congenital melanocytic naeval cells: evidence for a potential role as a chemopreventive agent , 2001, Melanoma research.
[183] S. Telford,et al. Atovaquone and azithromycin for the treatment of babesiosis. , 2000, The New England journal of medicine.
[184] Paul A. Wender,et al. Synthesis and biological evaluation of a new class of bryostatin analogues: the role of the C20 substituent in protein kinase C binding , 2000 .
[185] M. Wills,et al. Chemistry and clinical biology of the bryostatins. , 2000, Bioorganic & medicinal chemistry.
[186] C. Farquhar. Extracts from the "clinical evidence". Endometriosis. , 2000, BMJ.
[187] P. Wender,et al. Synthesis and Biological Evaluation of Bryostatin Analogues: The Role of the A-Ring. , 2000 .
[188] D J Newman,et al. The influence of natural products upon drug discovery. , 2000, Natural product reports.
[189] K. Hinkle,et al. The rational design of potential chemotherapeutic agents: Synthesis of bryostatin analogues , 1999, Medicinal research reviews.
[190] S. Looareesuwan,et al. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. , 1999, The American journal of tropical medicine and hygiene.
[191] K. Hinkle,et al. Synthesis and biological evaluation of fully synthetic bryostatin analogues , 1998 .
[192] P. Wender,et al. The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[193] Makoto Shiozaki,et al. Synthesis of the First Members of a New Class of Biologically Active Bryostatin Analogues , 1998 .
[194] Neal Rosen,et al. Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.
[195] G. Pettit. Progress in the discovery of biosynthetic anticancer drugs. , 1996, Journal of natural products.
[196] I. Paterson,et al. Total Synthesis of Bioactive Marine Macrolides , 1995 .
[197] S. Pillemer,et al. Minocycline in Rheumatoid Arthritis: A 48-Week, Double-Blind, Placebo-Controlled Trial , 1995, Annals of Internal Medicine.
[198] L. Neckers,et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[199] S. Follansbee,et al. Oral Atovaquone Compared with Intravenous Pentamidine for Pneumocystis carinii Pneumonia in Patients with AIDS , 1994, Annals of Internal Medicine.
[200] Stuart L. Schreiber,et al. A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.
[201] D. Marmé,et al. Gö 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[202] Craig J. Forsyth,et al. Total synthesis of halichondrin B and norhalichondrin B , 1992 .
[203] J. Heitman,et al. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast , 1991, Science.
[204] A. Fauci,et al. Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells , 1990, Journal of virology.
[205] K. Koehler,et al. Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[206] S. Amano,et al. Dactylosporangium fulvum sp. nov. , 1986 .
[207] T. Hickey,et al. Irritant contact dermatitis in humans from phorbol and related esters. , 1981, Toxicon : official journal of the International Society on Toxinology.
[208] S. Sehgal,et al. Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. , 1978, The Journal of antibiotics.
[209] D. Weedon,et al. Home treatment of basal cell carcinoma. , 1976, The Medical journal of Australia.
[210] S. Sehgal,et al. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.:II. FERMENTATION, ISOLATION AND CHARACTERIZATION , 1975 .
[211] S. Sehgal,et al. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.
[212] C. Deboer,et al. Geldanamycin, a new antibiotic. , 1970, The Journal of antibiotics.
[213] V. Arioli,et al. Rifamycins. XLI. A new class of active semisynthetic rifamycins. N-substituted aminomethyl derivatives of rifamycin SV 2. , 1965, Journal of medicinal chemistry.
[214] G. Carraz,et al. [Pharmacodynamic properties of N-dipropylacetic acid]. , 1963, Therapie.
[215] CYRIL M. HARRIS,et al. The New York Academy of Sciences , 1881, Nature.
[216] H. Umezawa,et al. A new antibiotic, pyridomycin. , 1953, The Journal of antibiotics.